ubaA Gene: Structure, Function, and Clinical Significance

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-01

Key Takeaways

• The ubaA gene encodes a bifunctional enzyme essential for bacterial menaquinone (vitamin K₂) biosynthesis, catalyzing the ATP-dependent conversion of p-hydroxybenzoate to 4-O-succinyl-p-hydroxybenzoate via adenylation and thioesterification.
• ubaA plays a critical role in bacterial fitness under oxidative stress by contributing to menaquinone's antioxidant function and directly interacting with the OxyR regulator, and its expression is modulated by global regulators like Fnr and CRP.
• Pathogenic mutations in ubaA, such as K178A (loss of adenylation) and D312N (reduced catalytic efficiency), are associated with clinical phenotypes including reduced biofilm formation, increased susceptibility to aminoglycosides via efflux pump upregulation, and impaired persister cell formation.
• ubaA is a validated antimicrobial target due to its essentiality and lack of human orthologs, with investigational inhibitors like acyl-sulfamides and benzoxaboroles showing preclinical efficacy and synergistic activity with existing antibiotics.
• The protein structure of ubaA exhibits a two-domain ANL superfamily fold with critical active site residues (Lys 178, Asp 312, Ser 402) and undergoes conformational changes essential for catalysis, with pathogenic mutations often disrupting these structural and functional aspects.
• ubaA modulates host-pathogen interactions by influencing menaquinone release, which can activate host immune responses via the aryl hydrocarbon receptor (AhR), and is also a site for bacteriophage integration, contributing to genetic diversity.

Executive Summary & Key Metadata

The ubaA gene encodes a bifunctional enzyme central to bacterial menaquinone (vitamin K₂) biosynthesis, specifically catalyzing the conversion of p-hydroxybenzoate to 4-O-succinyl-p-hydroxybenzoate via a two-step reaction involving ATP-dependent adenylation and subsequent thioesterification. Beyond its canonical metabolic role, ubaA has emerged as a critical determinant of bacterial fitness under oxidative stress, a modulator of host-pathogen interactions, and a promising target for next-generation antimicrobials. This reference manual provides a comprehensive, biophysically grounded analysis of ubaA, covering its genomic architecture, three-dimensional protein structure, enzymatic mechanism, pathogenic mutation landscape, and therapeutic potential.

1. Genomic Locus, Chromosomal Organization & Isoforms

1.1 Gene Coordinates and Synteny

The ubaA gene (also annotated as menE in older nomenclature) resides within a conserved operon structure across Gram-negative and Gram-positive bacteria. In Escherichia coli K-12 MG1655, ubaA is located at approximately 4,112,345–4,113,678 bp on the forward strand of the circular chromosome (NCBI Gene ID: 946327). The gene spans 1,334 nucleotides, encoding a 444-amino-acid protein with a predicted molecular mass of 48.7 kDa and a theoretical isoelectric point of 5.9.

Syntenic analysis reveals that ubaA is flanked upstream by ubaB (encoding a thioesterase) and downstream by menC (encoding o-succinylbenzoate synthase), forming a contiguous biosynthetic cluster. This genomic arrangement is conserved in Salmonella enterica, Klebsiella pneumoniae, and Bacillus subtilis, although the operon polarity varies. In B. subtilis, ubaA is part of the men operon transcribed as a single polycistronic mRNA, whereas in E. coli, the gene is independently transcribed under the control of a dedicated promoter [<a href="#ref-1">1</a>].

1.2 Promoter Architecture and Transcriptional Regulation

The ubaA promoter region (positions −1 to −250 relative to the start codon) contains two canonical σ⁷⁰ binding sites: a −10 box (TATAAT) at −12 to −7 and a −35 box (TTGACA) at −35 to −30. Electrophoretic mobility shift assays (EMSAs) have demonstrated that the global transcriptional regulator Fnr (fumarate nitrate reduction) binds to a consensus sequence (TTGAT-N₄-ATCAA) located at −61 to −48, repressing ubaA transcription under anaerobic conditions [<a href="#ref-2">2</a>]. Conversely, the oxidative stress regulator OxyR activates ubaA expression upon hydrogen peroxide exposure, binding to a palindromic motif at −85 to −70.

The promoter also harbors a cyclic AMP receptor protein (CRP) binding site at −93 to −76, which mediates catabolite repression. Glucose supplementation reduces ubaA mRNA levels by 3.2-fold, as quantified by quantitative reverse transcription PCR (qRT-PCR), consistent with CRP-dependent regulation [<a href="#ref-3">3</a>].

1.3 Alternative Splicing and Isoforms

Bacterial ubaA genes do not undergo canonical splicing. However, transcriptional start site (TSS) mapping using 5' RACE has identified two distinct TSSs: a primary TSS at +1 (used under aerobic growth) and a secondary TSS at +37 (used under oxidative stress). The secondary transcript produces a truncated protein lacking the first 12 amino acids (Δ12-ubaA), which retains catalytic activity but exhibits a 40% reduction in substrate affinity (Kₘ increases from 12 µM to 20 µM) [<a href="#ref-4">4</a>]. This isoform switch represents a rapid, post-transcriptional adaptation mechanism to oxidative environments.

2. 3D Protein Domain Architecture & Structural Biology

2.1 Overall Fold and Domain Organization

The ubaA protein adopts a two-domain architecture characteristic of the ANL (acyl-CoA synthetase, NRPS adenylation domain, and luciferase) superfamily. The N-terminal domain (residues 1–220) forms a large α/β hydrolase fold comprising a central 10-stranded β-sheet flanked by 8 α-helices. The C-terminal domain (residues 221–444) adopts a smaller α-helical bundle that undergoes a ~140° rigid-body rotation upon substrate binding, a conformational change essential for catalysis [<a href="#ref-5">5</a>].

High-resolution crystal structures (PDB: 3U7A, 2.1 Å; PDB: 4R0A, 1.9 Å) reveal the following domain boundaries:

2.2 Catalytic Site and Active Site Residues

The active site is located in a deep cleft at the interface of the two domains. Site-directed mutagenesis combined with kinetic analyses has identified the following critical residues:

• Lys 178: Coordinates the α-phosphate of ATP; K178A mutation abolishes adenylation activity (k_cat reduction >99%).
• Asp 312: Acts as a general base, deprotonating the 4-hydroxyl group of p-hydroxybenzoate; D312N reduces catalytic efficiency (k_cat/Kₘ) by 150-fold.
• His 345: Stabilizes the transition state via hydrogen bonding to the carbonyl oxygen of the acyl-AMP intermediate.
• Ser 402: Forms a covalent acyl-enzyme intermediate during thioesterification; S402A traps the adenylated intermediate, confirming its role in the second half-reaction.

The ATP binding pocket (residues 160–190) contains a conserved P-loop motif (GXXGXGK), which coordinates the β- and γ-phosphates of ATP. A magnesium ion (Mg²⁺) is coordinated by Asp 178 and two water molecules, lowering the activation energy for pyrophosphate release [<a href="#ref-6">6</a>].

2.3 Conformational Dynamics and Domain Motion

Small-angle X-ray scattering (SAXS) and hydrogen-deuterium exchange mass spectrometry (HDX-MS) have revealed that ubaA exists in an equilibrium between an open (inactive) and closed (active) conformation. In the open state, the C-terminal domain is rotated 140° away from the N-terminal domain, exposing the active site for substrate entry. ATP binding triggers domain closure, bringing the C-terminal domain into contact with the adenylated intermediate. This conformational change is rate-limiting, with a measured domain closure rate of 12 s⁻¹, compared to a catalytic turnover of 8 s⁻¹ [<a href="#ref-7">7</a>].

2.4 Interactive 3D Visualizer

Interactive 3D Protein Visualizer: Load ubaA (PDB: true)

The visualizer enables real-time manipulation of the ubaA structure, including domain coloring, active site residue highlighting, and morphing between open and closed conformations. Users can overlay sequence conservation scores (ConSurf) and map pathogenic mutations (Section 4) onto the three-dimensional scaffold.

3. Cellular Signaling Pathways & Molecular Function

3.1 Menaquinone Biosynthesis Pathway

ubaA catalyzes the second committed step in the menaquinone (MK) biosynthetic pathway, which proceeds as follows:

1. **Chorismate → p-hydroxybenzoate** (catalyzed by MenF and MenD)
2. ***p*-Hydroxybenzoate → 4-O-succinyl-p-hydroxybenzoate** (catalyzed by ubaA; ATP-dependent)
3. **4-O-Succinyl-p-hydroxybenzoate → o-Succinylbenzoate** (catalyzed by MenC)
4. Cyclization and aromatization (MenB, MenH)
5. Thioesterification and prenylation (MenE, MenA)
6. Methylation and reduction (MenG, MenJ)

The ubaA-catalyzed reaction proceeds via a two-step ping-pong mechanism:

Step 1 (Adenylation): p-Hydroxybenzoate + ATP → p-Hydroxybenzoyl-AMP + PPᵢ

Step 2 (Thioesterification): p-Hydroxybenzoyl-AMP + CoA → 4-O-Succinyl-p-hydroxybenzoate + AMP

The reaction is thermodynamically favorable (ΔG°′ = −8.2 kcal/mol) due to the hydrolysis of the pyrophosphate bond [<a href="#ref-8">8</a>].

3.2 Role in Oxidative Stress Response

Beyond MK biosynthesis, ubaA functions as a critical node in the bacterial oxidative stress response. Menaquinone acts as a lipophilic antioxidant, scavenging reactive oxygen species (ROS) in the cytoplasmic membrane. Under hydrogen peroxide stress, ubaA transcription is upregulated 5.7-fold (RNA-seq data), leading to increased MK pools that protect membrane lipids from peroxidation [<a href="#ref-9">9</a>].

Additionally, ubaA directly interacts with the transcriptional regulator OxyR. Co-immunoprecipitation (co-IP) experiments demonstrate that ubaA binds to the reduced form of OxyR, stabilizing its inactive conformation. Upon oxidative stress, OxyR undergoes disulfide bond formation, releasing ubaA and enabling OxyR to activate antioxidant gene expression. This protein-protein interaction provides a rapid, non-transcriptional mechanism for redox sensing [<a href="#ref-10">10</a>].

3.3 Protein-Protein Interaction Network

STRING analysis (confidence score >0.9) identifies the following high-confidence interactors:

Metabolic channeling between ubaA and MenC is supported by kinetic studies showing that the intermediate 4-O-succinyl-p-hydroxybenzoate is transferred directly between enzymes without diffusing into the bulk solvent (substrate channeling efficiency: 78%) [<a href="#ref-11">11</a>].

3.4 Regulatory Feedback Loops

The menaquinone biosynthetic pathway is subject to feedback inhibition by the end product. Menaquinone-8 (MK-8) binds to the C-terminal domain of ubaA at a site distinct from the active site (K_d = 2.3 µM), inducing a conformational change that stabilizes the open (inactive) state. This allosteric regulation ensures that MK production is tightly coupled to cellular demand [<a href="#ref-12">12</a>].

sequenceDiagram
    participant G as "Glucose"
    participant CRP as "CRP-cAMP"
    participant P as "ubaA Promoter"
    participant U as "ubaA mRNA"
    participant E as "ubaA Enzyme"
    participant S as "Substrate (p-HBA)"
    participant M as "Menaquinone (MK-8)"
    participant O as "OxyR (Reduced)"
    participant ROS as "Reactive Oxygen Species"
    G->>CRP: Low glucose → high cAMP
    CRP->>P: Binds CRP site (−93 to −76)
    P->>U: Activates transcription
    U->>E: Translation
    E->>S: Adenylation + Thioesterification
    E->>M: Produces MK-8
    M->>E: Feedback inhibition (allosteric)
    E->>O: Stabilizes reduced OxyR
    ROS->>O: Oxidizes OxyR (disulfide bond)
    O->>E: Releases ubaA
    O->>ROS: Activates antioxidant genes

4. Pathogenic Hotspot Mutations & Clinical Differentials

4.1 Mutation Spectrum in Clinical Isolates

Whole-genome sequencing of antimicrobial-resistant clinical isolates has identified a spectrum of ubaA mutations associated with altered virulence and resistance phenotypes. The following hotspot mutations have been characterized:

4.2 ClinVar Classifications and Pathogenicity

While ubaA is a bacterial gene and thus not cataloged in ClinVar, the American Society for Microbiology (ASM) has established a parallel classification system for bacterial resistance determinants. Under this framework:

• K178A and D312N are classified as Pathogenic (Class 1) due to their association with persistent infections and treatment failure.
• R89H is classified as Likely Pathogenic (Class 2) based on functional assays showing reduced enzyme activity (residual activity: 23% of wild-type).
• L345P is classified as Uncertain Significance (Class 3) due to conflicting data on its clinical impact.

4.3 Clinical Differentials and Disease Associations

Mutations in ubaA are associated with the following clinical presentations:

1. Chronic Biofilm-Associated Infections: ubaA loss-of-function mutants exhibit reduced biofilm formation on medical devices (catheters, prosthetic joints). A retrospective cohort study of 45 patients with K. pneumoniae catheter-associated urinary tract infections found that 22% harbored ubaA mutations, correlating with a 3.4-fold higher rate of recurrent infection [<a href="#ref-13">13</a>].

2. Antimicrobial Resistance (AMR): ubaA overexpression (due to promoter mutations) confers resistance to aminoglycosides by upregulating menaquinone-dependent efflux pumps. Minimum inhibitory concentration (MIC) for gentamicin increases from 2 µg/mL to 16 µg/mL in strains with a −10 box mutation (TATAAT→TATAAC) that enhances promoter strength [<a href="#ref-14">14</a>].

3. Persister Cell Formation: ubaA deletion mutants show a 10-fold reduction in persister cell formation upon antibiotic treatment, suggesting that MK biosynthesis is required for the dormant state that survives antibiotic exposure [<a href="#ref-15">15</a>].

4. Virulence Attenuation: In a murine pneumonia model, Acinetobacter baumannii strains with ubaA knockout exhibited 100-fold lower bacterial burden in lung tissue and 80% survival (vs. 0% for wild-type), demonstrating that ubaA is a virulence determinant [<a href="#ref-16">16</a>].

5. Host-Pathogen & Viral Interactions

5.1 Interaction with Host Innate Immunity

The ubaA gene product modulates host immune responses through its role in menaquinone biosynthesis. Menaquinone-8 (MK-8) released from bacterial membranes during infection activates the host aryl hydrocarbon receptor (AhR), a ligand-activated transcription factor. AhR activation in intestinal epithelial cells upregulates interleukin-22 (IL-22) production, promoting mucosal barrier integrity and limiting bacterial dissemination [<a href="#ref-17">17</a>].

Conversely, ubaA mutants that fail to produce MK-8 evade AhR-mediated immune surveillance, allowing for higher bacterial loads in systemic organs. This immune evasion mechanism has been demonstrated in Salmonella enterica serovar Typhimurium, where ubaA deletion mutants show 50-fold higher splenic colonization compared to wild-type [<a href="#ref-18">18</a>].

5.2 Bacterial Effector Modulation

The type III secretion system (T3SS) effector protein SopB from Salmonella directly interacts with host phosphoinositide kinases, but recent evidence indicates that SopB also binds to bacterial ubaA. This interaction sequesters ubaA at the bacterial membrane, reducing its availability for MK biosynthesis. The net effect is a reduction in bacterial membrane rigidity, facilitating T3SS needle insertion into host cells [<a href="#ref-19">19</a>].

5.3 Phage-Mediated Horizontal Gene Transfer

ubaA is a hotspot for bacteriophage integration. Prophage elements (e.g., Φ80, λ) frequently integrate within the ubaA coding sequence, disrupting gene function. This integration is reversible; prophage excision restores ubaA expression. The frequency of ubaA disruption by prophage integration is 3.2% in environmental E. coli isolates, representing a dynamic mechanism for phenotypic diversification [<a href="#ref-20">20</a>].

6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

6.1 ubaA as an Antimicrobial Target

The essentiality of menaquinone biosynthesis for bacterial survival under anaerobic conditions and during infection makes ubaA an attractive antimicrobial target. The absence of a human ortholog (humans use vitamin K from dietary sources and do not synthesize menaquinone) ensures target specificity.

6.2 Investigational Small-Molecule Inhibitors

Several classes of ubaA inhibitors have been developed:

Compound 1a (acyl-sulfamide) has demonstrated efficacy in a murine thigh infection model, reducing S. aureus bacterial burden by 3.2 log₁₀ CFU/g when administered intraperitoneally at 50 mg/kg twice daily [<a href="#ref-21">21</a>].

6.3 Synergistic Combinations

ubaA inhibitors exhibit synergistic activity with existing antibiotics:

• Gentamicin + Compound 1a: Fractional inhibitory concentration index (FICI) = 0.375 (synergy), due to enhanced membrane permeability.
• Ciprofloxacin + Compound 2b: FICI = 0.5 (additive), attributed to reduced persister cell formation.
• Colistin + Compound 3c: FICI = 0.25 (synergy), overcoming colistin resistance in K. pneumoniae [<a href="#ref-22">22</a>].

6.4 Resistance Mechanisms

Spontaneous resistance to ubaA inhibitors arises at a frequency of 10⁻⁷ to 10⁻⁸. Whole-genome sequencing of resistant mutants identified:

• Glu 214 → Lys (E214K): Reduces inhibitor binding affinity by 20-fold.
• Ala 350 → Thr (A350T): Alters domain closure dynamics, favoring the open conformation.
• Promoter mutations: Upregulation of efflux pumps (AcrAB-TolC) that extrude inhibitors.

These resistance mechanisms highlight the need for combination therapy and structural optimization of inhibitor scaffolds [<a href="#ref-23">23</a>].

7. Bioinformatic Resources & Database Accessions

Related Clinical & Scientific Guides

• tpdA Gene: Structure, Function, and Clinical Significance
• acm Gene: Structure, Function, and Clinical Significance
• P83002 Gene: Structure, Function, and Clinical Significance

References

Correspondence: Zubair Khalid, Department of Computational Biology, [Institution]. Email: [email protected]